Superworth

Q32 Bio QTTB

Drug Manufacturers - General, Healthcare
$8.71
−2.24%
Market cap
$259.3M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
7.4×
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for QTTB, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$1.9M+132%$0$0$0$0$0n/an/an/an/an/an/a
R&D$7.5M−71%$1.5M−94%$9.8M+24%$13.4M+67%$14.3M+92%$10.5M+597%$7.1M−28%$5.2M−62%$3.6M−75%$3.3M−69%$3.2M−55%$4.3M−18%
SG&A$2.2M−72%$7.9M−3%$5M+108%$4.5M+83%$4.5M+104%$4M−50%$5.1M+2%$4M−11%$4M−10%$4.5M+14%$4.5M−12%$4.9M+21%
−$7.8M−76%−$12.1M−65%−$14.8M+101%−$17.9M+146%−$18.8M+141%−$14.5M+20%−$12.2M−18%−$9.2M−49%−$7.6M−60%$45.9M−$7.7M−37%−$9.1M−1%
Pre-tax income−$14M−56%−$2.2M−94%$1.2M−$15.5M+167%−$17.6M+26%−$14.2M+557%−$11M−$9.5M−39%−$7.4M−58%$57.7Mn/an/a
−$65K$0$0$0$0$21K$0$0n/an/an/an/a
Net income−$14M−58%−$27.1M−21%$1M−$17M+192%−$17.6M+25%−$14.2M−48%−$11M−$9.5M−44%−$7.4M−58%$57.7M−$7.6M−31%−$8.9M−6%
−$40.52+282%$75.14−$6.33−68%−$1.42−92%−$1.46−96%n/a−$0.90−86%−$0.78−45%−$0.60−59%n/a−$0.54−40%−$0.44−44%
346.3K−89%354.3K−89%2.3M+577%12M+3339%12.1M+3387%n/a12.2M+423%12.2M+2%12.2M+1%n/a14.1M+16%20.3M+67%

EPS, diluted: 7 periods, Q4 FY17 to Q4 FY23: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY17 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Q32 Bio's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
QTTBQ32 Bio$259.3Mn/mn/an/mn/mn/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
Peer median$508.6M11.4×13.5×1.4×+7%13.6%

More on Q32 Bio

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .